The immunologic aspects in hormone receptor positive breast cancer

Autor: Gizem Oner, Sevilay Altintas, Zafer Canturk, Wiebren Tjalma, Christophe Van Berckelaer, Glenn Broeckx, Karen Zwaenepoel, Maria Tholhuijsen, Yannick Verhoeven, Zwi Berneman, Marc Peeters, Patrick Pauwels, Peter A van Dam

Publikováno v: Cancer Treatment and Research Communications, Vol 25, Iss , Pp 100207- (2020)

Background: : Although hormone receptor positive/HER2-negative (HR +/HER2-) breast cancer is the most diagnosed breast cancer type, the immunologic aspects HR positive breast cancer (BC) has been neglected until recently. The purpose of this paper is

Externí odkaz: https://doaj.org/article/9d4f83d0ae5f4732834520ae8907a941

RANK-RANKL Signaling in Cancer of the Uterine Cervix: A Review

Autor: Peter A. van Dam, Yannick Verhoeven, Julie Jacobs, An Wouters, Wiebren Tjalma, Filip Lardon, Tim Van den Wyngaert, Jonatan Dewulf, Evelien Smits, Cécile Colpaert, Hans Prenen, Marc Peeters, Martin Lammens, Xuan Bich Trinh

Publikováno v: International Journal of Molecular Sciences, Vol 20, Iss 9, p 2183 (2019)

RANK ligand (RANKL) is a member of the tumor necrosis factor alpha superfamily of cytokines. It is the only known ligand binding to a membrane receptor named receptor activator of nuclear factor-kappa B (RANK), thereby triggering recruitment of tumor

Externí odkaz: https://doaj.org/article/b754382132144d59a3b8ce2313eed8c6

Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update

Autor: Jorrit De Waele, An Wouters, Evelien Smits, Filip Lardon, Yannick Verhoeven, Peter van Dam, Delphine Quatannens, Xuan Bich Trinh

Publikováno v: International Journal of Molecular Sciences
International journal of molecular sciences
International Journal of Molecular Sciences, Vol 22, Iss 1807, p 1807 (2021)

Even though cervical cancer is partly preventable, it still poses a great public health problem throughout the world. Current therapies have vastly improved the clinical outcomes of cervical cancer patients, but progress in new systemic treatment mod

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3c932b0c2ac360e2bc9c13cb2dfc13e
http://europepmc.org/articles/PMC7917788

Immuno-PET molecular imaging of RANKL in cancer

Autor: Tim Van den Wyngaert, Christel Vangestel, Karen Zwaenepoel, Yannick Verhoeven, Jorrit De Waele, Filipe Elvas, Peter van Dam, Jonatan Dewulf

Publikováno v: Cancers
Cancers, Vol 13, Iss 2166, p 2166 (2021)
Volume 13
Issue 9

Simple Summary Receptor activator of the nuclear factor kappa B ligand (RANKL) has been recently identified as a target of interest in the tumor microenvironment (TME), specifically in facilitating an immunosuppressive environment and subsequent resi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11469755edfea3e251cd8e1163fc5037
https://repository.uantwerpen.be/docstore/d:irua:6334

The Non-Bone-Related Role of RANK/RANKL Signaling in Cancer

Autor: Peter A, van Dam, Yannick, Verhoeven, Xuan B, Trinh

Publikováno v: Advances in experimental medicine and biology. 1277

RANK ligand (RANKL) is a member of the tumor necrosis factor alpha superfamily of cytokines. It is the only known ligand binding to a membrane receptor named receptor activator of nuclear factor-kappa B (RANK), thereby triggering recruitment of TNF r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c1c24b2aa3be6eedff863c511825b34a
https://pubmed.ncbi.nlm.nih.gov/33119864